ophthalmic artery and its branches. The proposed theory is that of retrograde pressure induced embolization of material through the vascular anastomosis of arterial vessels in the facial region with a final common pathway ending in the end arteries of the retinal artery. 4, 5 The Aesthetic Interventional Induced Visual Loss (AIIVL) A report in 2017 recommended the availability a "blindness safety kit" with a protocol to follow if such a complication should occur. 6 A previous review also noted that practitioners ".must be trained to recognise symptoms, institute immediate actions and refer patients without delay to dedicated specialists for definitive and supportive management". 7 There is however a lack of a standard protocol for the treatment of this complication, and there are no Level I recommendations available for practitioners to follow.
The guidance developed by the AIIVL Consensus Group is based on the scenario of visual loss due to soft tissue injection with hyaluronic acid (HA); the basic principles of the treatment pathway for non-HA products may be applied, although hyaluronidase would not be effective.
In reviewing the evidence base, blindness following injection was initially described in 1963 8 and more recent reports show that the pattern of involvement of the surrounding periocular tissues is variable. 9 The ophthalmological literature describes a clinical condition of Central Retinal Artery Occlusion (CRAO). 10, 11 Patients who smoke, are hypertensive, have a high body mass index, high serum lipid levels, diabetes, and cardiac disease, have important modifiable risk factors associated with retinal emboli; it can be hypothesized that these patients may bear the higher risk for AIIVL.
The guidance of the AIIVL group draws on the corollary between this clinical condition and that of the complication by occlusion by an embolus of HA.
| CONSENSUS GUIDANCE
The group provides guidance on separate aspects:
1. Pre-and peritreatment advice to minimize the risk of general and specific complications;
2. Immediate management of patients with visual loss at the clinic and at home;
3. Specific advice that specialist units may follow;
4. Further advice to the practitioner.
| General advice
The group felt that the following was important for all practitioners injecting products in the head and neck region:
The potential for visual loss and skin necrosis must be on consent forms and be explicitly discussed with the patient. Although this complication is very rare, informed consent requires that the practitioner discusses this potential life-altering condition with the patient. Surgeons who perform surgical blepharoplasty will discuss the potential of visual loss and in not doing so would be deemed below the standard of practice of a reasonably competent practitioner on that field. The consequences of visual loss are so devastating that the group felt that this aspect of the potential complication should be openly discussed with the patient (Consensus Recommendation).
All practitioners performing injectable treatments in the head and neck area must have a thorough knowledge of facial anatomy with respect to vessels (layers of face and where vessels may be found).
There is much information available and being reported regarding When using a cannula (single-entry sites), care should be taken to minimize adjacent skin contact on cannula entry so as to avoid the introduction of skin commensals at each entry. Practitioners should consider keeping the cannula clean between passes through the skin. With multiple injection points (eg, needle), it may be applicable to consider further skin cleaning between injections to reduce bacterial load and change the needle for patient comfort (Clinical Guidelines).
While performing injections, these should be delivered slowly with minimal pressure, to minimize trauma and also the potential for embolism if a vessel has unknowingly been breached. There should be caution with mechanical injection systems to avoid high pressure
injections. The precise pressure required to cause an embolic phenomenon has not been verified (Consensus Recommendations).
There have been reports that when injecting a bolus, the volume of injectate should be a limited volume of less than 0.1 mL per bolus 12 (Publication).
The cannula size used to inject should be 25G or greater diameter. There is opinion and views that a 27G cannula has a great potential to penetrate arterial walls. Cannulas with a gauge of 25 or larger diameter may have less risk of puncturing the arterial wall.
Thin needles and cannulas (diameter 27G or less) may enter vessels and also need high pressure to initiate flow. This is, however, not acknowledged by all the experts. Alternatively, a thinner needle makes it difficult to deliver large volume in one bolus quickly so may make it less likely to cause visual loss ( Table 1 ).
The group went on to consider possible scenarios in which a patient may present following an injection of HA-based filler. The two possible presentations are as follows:
1. Immediate visual loss with patient in clinic; and 2. Delayed presentation-patient not in clinic.
| Immediate visual loss
In the eventuality of a patient presenting with immediate visual loss, the first action of the practitioner should:
• stop injecting immediately;
• Ask the patient to start to rebreathing into a paper bag to increase the carbon dioxide concentration in the bloodstream.
This is in keeping with recommendations for CRAO. The principle of retinal artery vasodilatation was considered as a priority to encourage the movement of the emboli into the peripheral portions of the vascular system (Publication for CRAO);
• Give oral aspirin immediately as an oral regimen of 2 pills of 325 mg daily to try to prevent further clot formation due to vascular compromise (and an antacid to prevent aspirin-associated gastritis). The duration of aspirin treatment would depend on the clinical scenario and whether improvement is seen, but a one week course is recommended (Publication for Vascular Occlusion);
• Sublingual GTN may be administered of potentiate further vascular dilatation and encourage movement of the product toward the periphery of the retinal system (Publication for Vascular Occlusion);
• Commence ocular massage to theoretically cause the embolus to travel physically displace emboli toward the periphery of the retinal system. This should be instituted immediately in conjunction with the above maneuvers.
Without any additional delay, the patient should be transferred to a specialist facility (Eye Hospital/A&E). There is some evidence from the literature on CRAO to suggest that after 90 minutes there is irreversible loss of vision that is progressive. Specialist treatment at an appropriate facility should be instituted as soon as possible to optimize all possible treatment pathways and provide professional support to the patient (Publication on CRAO).
| Delayed presentation-patient not in clinic
The group felt that the same management pathway as for immediate 
| Specific interventions at specialist facility
The group were concerned that in many cases patients who presented at emergency facilities were met by specialists who were not up to date with any of the specific guidelines. The AIIVL group looked at the possible interventions and have drawn up some guidance that would assist the specialist centers in starting emergency treatments.
In addition to the guidance proposed for the initial care, the specialist facility should consider the following interventions. As time is of the essence, it is important that the patient care is not delayed to If this intervention were to be attempted, it must be considered in the context that, retrobulbar injections pose a risk to the patient.
Inferotemporal peribulbar injection of hyaluronidase is probably less of a risk than retrobulbar injection (although there is no confirmed evidence of effectiveness). However, it could be attempted in a specialist setting. The inferotemporal area represents the narrowest portion of CRA is as it pierces the dura of the optic nerve and would be a target area for the enzyme to penetrate the CRA. The specific doses of hyaluronidase have not been elucidated; however, it would appear appropriate to consider injecting 2-4 mL (1500 IU). It would be advisable to consider repeated retinal arterial observation and repeated infusion of hyaluronidase on an hourly basis (although this is only a consensus opinion).
Superselective Intra-arterial thrombolysis has also been considered 15, 16 ; however, there has been no convincing evidence of reperfusion. There is also a high risk of adverse events including cerebrovascular hemorrhage.
Direct intraocular injection of hyaluronidase has been attempted in an animal model in an attempt to deliver the enzyme directly near to the site of the embolus.
Recent use of IV Urokinase & hyaluronidase in high doses has been shown to be very effective in an animal model. 17 This has been reported to be effective in one case report. 18 The presumed mechanism is that proximal to the emboli, there is vascular stasis, which results in a thrombus. The thrombolytic agent allows the hyaluronidase to reach the HA emboli, and therefore, the combined approach is more effective than the agents when administered separately.
Overall, the results for patients presenting with no light perception following an HA emboli have been very poor. It is however imperative that any intervention is instituted within an hour of injury. Indirect evidence from rhesus monkeys with CRAO reveals that the retina could recover after 98 minutes; however after 105 minutes, the retina was irreversibly damaged. 19 
| Patient support/administration
The group considered that the follow-up of the patient including support was important and the injecting practitioner should take on this responsibility in collaboration with the specialist facility.
Following the adverse event and institution of the management plan as discussed above, the following aspects should be addressed (Consensus Recommendations):
• Inform the product manufacturer (medical affairs) regarding the adverse event and the product(s) used, volumes, and all details of the product.
• The national medical device authority (MHRA in the UK) must be informed regarding this adverse event.
• Liaise with the specialist facility and discuss the potential serious outcome of the adverse event. The practitioner has a duty of candor to be transparent in their actions concerning this event.
• Provide ongoing support for the patient's family and keep in close contact with the patient during this period. The patient may feel vulnerable and angry, and it will be important to provide support to them.
There will be important administrative aspects that the practitioner will need to address (Good Medical Practice):
• The relevant medical indemnity provider must be informed.
• Details of all the events preceding and the interventions/action taken must be accurately recorded including: treatment schedule product use/volume & site injected needle/cannula including size.
• All relevant photographs of the patient should be available.
• All communications between the specialist facility, patient and practitioner should be documented (Table 2) 3 | DISCUSSION There continues to be discussion on the role of retrobulbar infiltration of hyaluronidase; the risks of this technique and lack of efficacy in recent reports 17 when balanced with the guidance for CRAO have led us to provide guidance that has some clinical basis including techniques that are readily available to the practitioner and specialist.
The experimental studies using IV hyaluronic acid and thrombolytic therapy may provide more specific treatments and we await further developments in this area. The most important aspect in this is the essential knowledge of head and neck vascular anatomy and the techniques of injection to avoid this adverse event.
| CONCLUSION
An immediate diagnosis and treatment of visual loss using the guidance provided may be of critical importance in managing this adverse event. Unfortunately, the prognosis for vision return is grave. There is no robust Level I evidence-based treatment that can restore vision and no clear evidence that the complication of vascular occlusion can be avoided even with optimal technique in expert HUMZAH ET AL.
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hands. We hope that the guidance we have provided will be evaluated and encourage further clinical research.
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